GlucoTrack (GCTK) investor relations material

Executive summary

• Submitted IDE application to FDA for a fully implantable continuous blood glucose monitor (CBGM), targeting U.S. clinical trial launch in 2H 2026, with positive first-in-human results and peer-reviewed publications supporting technology longevity and accuracy.

• Closed an Australian feasibility study to refocus on product improvements and U.S. regulatory pathway.

• Strengthened balance sheet by reducing debt and drawing on equity line of credit, but faces ongoing liquidity challenges and substantial doubt about ability to continue as a going concern.

• Received Nasdaq delisting notice due to non-compliance with minimum bid price and cumulative reverse stock splits; intends to appeal.

• Held third Patient Advisory Board meeting to gather patient insights on device use and healthcare provider education.

Financial highlights

• Net loss for Q1 2026 was $4,334, down from $6,833 in Q1 2025, mainly due to lower other expenses and a decrease in non-cash derivative liability changes.

• Research and development expenses increased to $2,132 (Q1 2026) from $1,871 (Q1 2025), reflecting higher product development and preclinical costs.

• General and administrative expenses rose to $2,071 from $1,627 year-over-year, driven by higher professional fees and personnel costs.

• Cash and cash equivalents at March 31, 2026, were $3,929, down from $7,383 at year-end 2025, reflecting $4.1M used in operations and $0.6M from financing.

• Accumulated deficit reached $156,172 as of March 31, 2026.

Outlook and guidance

• Existing cash runway expected to last into early Q3 2026, supporting the planned initiation of U.S. clinical trials, but additional capital will be required.

• Expects research and development expenses to increase as clinical trial activities expand.

• Plans to finance operations through further equity or debt offerings, but no assurance of success.

• Plans to present additional clinical data at industry conferences as it becomes available.